English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Methoxy polyethylene glycol epoetin beta which has a long half-life is developed to provide stable control of hemoglobin levels at extended administration intervals compared to darbepoetin alfa. The purpose of this study was to compare the patterns of use, efficiency of therapy and cost with undergoing hemodialysis patients. Electronic medical record system was used to examine administration frequency, hemoglobin response rate, achievement of target hemoglobin, drug costs. Administration frequency was once in 4 weeks with methoxy polyethylene glycol epoetin beta group and 3 times in 4 weeks with darbepoetin alfa group. Hemoglobin response rate was 61.5% in methoxy polyethylene glycol epoetin beta at the time of 16 weeks. It was not significantly different from 66.7% in darbepoetin alfa (P = 1.000). The drug cost for methoxy polyethylene glycol epoetin beta group was little higher than darbepoetin alfa group. However, there was no statistically significant difference (P = 0.164). Use of methoxy polyethylene glycol epoetin beta is as effective and safe as darbepoetin alfa managing renal anemia in hemodialysis patients. Methoxy polyethylene glycol epoetin beta’s extended administration interval improve patient’s compliance and enable effective anemia treatment.

Comparison of Usage and Effectiveness between Methoxy Polyethylene Glycol Epoetin Beta and Darbepoetin Alfa with Hemodialysis Patients